What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?

When Ardelyx, Inc. (NASDAQ:ARDX) reported its Q1 FY2026 results, its full merchandise gross was up 38% YoY, acknowledgment to 58% YoY surge successful IBSRELA gross and beardown XPHOZAH performance. While discussing IBSRELA, absorption laid retired plans to present astatine slightest $1 cardinal successful yearly gross successful 2029. What strengthens the lawsuit for the institution is its fiscal flexibility to marque further investments.

As stated by the President and CEO, Mike Raab,

"We're excited for this adjacent signifier of Ardelyx's improvement arsenic we execute connected our pipeline and research assorted outer opportunities that align with our ngo and halfway capabilities and conscionable our disciplined superior allocation approach."

With a 1-year instrumentality outperformance of 42.18% and upside imaginable of 133.16%, Ardelyx, Inc. (NASDAQ:ARDX) is among the champion low-priced stocks to get affluent successful 2026.

Ardelyx, Inc. (NASDAQ:ARDX) is simply a Massachusetts-based institution specializing successful treatments for underserved aesculapian needs. The institution offers a small-molecule therapy and a phosphate-absorption inhibitor to dainty irritable bowel syndrome and chronic kidney disease, respectively.

While we admit the imaginable of ARDX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.